Taken together, it is plausible that the controversy surrounding TGF-β treatment in solid tumors is the result of dual functions for TGF-β, which acts in a context-dependent manner to promote tumor progression in stroma cells and cell cycle re-entry in quiescent CSCs. Here, TGFB1 is linked to neoplasm.